Baudax Bio, Inc.

As of May 12, 2023, Baudax Bio, Inc. is considered overvalued and has moved from a risky valuation grade to "does not qualify," with significant financial distress indicated by a P/E ratio of 0.00 and a negative return of -100% over the past year compared to the S&P 500's positive return of 10.26%.

As of June 13, 2025, the market trend is mildly bearish, indicated by daily moving averages and weekly Bollinger Bands, despite some mixed signals from the weekly MACD and KST.

As of September 2023, Baudax Bio, Inc. has an unavailable market capitalization, with net sales of $0.31 million and a consolidated net profit of -$25.83 million over the last four quarters. As of December 2022, shareholder's funds were -$24.24 million, and total assets were $10.03 million.